AI Terminal
ILIKA PLC
Report Publication Announcement • May 11, 2022
7701_rns_2022-05-11_bcb3d0e2-07e3-4e8e-9383-f2bb958fde03.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0163L
Ilika plc
11 May 2022
Ilika plc
("Ilika" or the "Company")
Trading Update & Notice of Results
Analyst and Investor presentations
Ilika (AIM: IKA), a pioneer in solid-state battery technology, provides updates on trading, Stereax® manufacturing, and Goliath product development, as well as notice of its full year results for the year ended 30 April 2022.
Trading Update for FY22
Trading for the year ended 30 April 2022 has been in line with management expectations. The Company expects to announce revenues of approximately £0.5m (2021: £2.3m), and an EBITDA loss of around £7.0m (2021: EBITDA loss of £2.3m). Cash and cash equivalents at the period end were £23.4m (30 April 2021: £9.7m).
Stereax Manufacturing Update and Trading Update for FY23
Further to the official opening in December 2021 of its manufacturing facility for Stereax miniature solid-state batteries for industrial wireless sensors and medical implants, Ilika has been progressing facility process qualification to the point where it is now substantially complete. As indicated in the Company's Interim Results on 20 January 2022, product qualification has commenced, which involves production of initial batches of batteries and testing them against specification. Whilst a series of process optimisation cycles have been carried out to date, it is taking longer than previously anticipated to ensure that product batches reproducibly meet specification.
In terms of an update on Ilika's pipeline, the demand from potential customers is now weighted predominantly towards miniature medical device applications. The demand for such applications starts with device prototyping, followed by pre-clinical and clinical trials before regulatory approval and mass market roll-out, which has a longer regulatory approval cycle than industrial sensors. Ilika will match production volumes to customer demand.
The shift in the weighting of customer demand towards medical device applications combined with the expectation of optimisation cycles continuing into H2 FY23, means the Company now expects commercial sales to commence at the end of that period, later than originally anticipated. A number of the potential applications for Stereax exceed the capacity of Ilika's facility, which provides longer term opportunities for partnering and licensing.
Goliath Progress Update
Product development of Goliath, Ilika's large format battery for electric vehicles and customer appliances, has continued to progress to schedule, with significant improvements achieved in energy density (providing the potential for lighter weight battery packs) and power density (key for rapid charging). Ilika continues to explore opportunities for closer collaboration with strategic partners interested in aligning their product roadmaps with Goliath.
Notice of Results
Ilika expects to announce its full year results for the year ended 30 April 2022 on Wednesday 13 July 2022.
Analyst Briefing
The management team will be hosting an in-person analyst briefing on the day, Wednesday 13 July 2022, at 9.30am. Analysts who wish to attend should contact Lianne Applegarth at Walbrook PR on +44(0)20 7933 8780 or email [email protected] to register.
Investor Presentation
An investor presentation will be held on the day, Wednesday 13 July 2022, at 4.30pm and will be hosted through the digital platform, Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Ilika plc via the following link: https://www.investormeetcompany.com/ilika-plc/register-investor or for more information please contact Walbrook PR at [email protected].
For more information contact:
| Ilika plc | +44 (0)23 8011 1400 |
| Graeme Purdy, Chief Executive | |
| Steve Boydell, Finance Director | |
| Liberum Capital Limited | +44 (0) 20 3100 2000 |
| Andrew Godber, Cameron Duncan, | |
| William Hall, Nikhil Varghese | |
| Berenberg (Joint Broker) | +44 (0) 20 3207 8700 |
| Emily Morris, Detlir Elezi, | |
| Milo Bonser, Mara Grasso | |
| Walbrook PR Ltd | +44 (0)20 7933 8780 or [email protected] |
| Lianne Applegarth | Mob: +44 (0)7584 391 303 |
| Nick Rome | Mob: +44 (0)7748 325 236 |
| Tom Cooper | Mob: +44 (0)7971 221 972 |
Note:
The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSFEFWSEESELI